Venus' meropenem receives market authorisation in Mexico

Venus Remedies has received market authorisation from COFEPRIS (La Comisión Federal para la Protección contra Riesgos Sanitarios) for its meropenem 500mg and 1,000mg in Mexico.Meropenem a broad spectrum anti-bacterial agent of carbapenem family, indicated as empirical therapy prior to the identification of causative organisms, or for disease caused by single or multiple susceptible bacteria in both adults and children with multiple serious infections.

According to Venus, at present, meropenem sales account for US$16.3 million in Mexico, of which, 80 per cent of which is accounted for by sales of the innovator product, AstraZeneca's Merrem, and rest with other local companies. The company is planning to launch the product in Mexico within the first quarter of fiscal year 2013 to 2014.

This article is tagged to:
Sector: Pharmaceuticals & Healthcare
Geography: Mexico, Mexico, Mexico, Mexico

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.